Lexicon Pharmaceuticals, Inc.’s Post

💊💉BRANDS SHOWING ROBUST GROWTH IN JUNE 2024💉💊 👉Indian pharmaceutical market registered over 8% growth in June 2024. 👉#Respiratory, #Antiinfectives and #Gastrointestinal therapies saw double-digit value growth of 19.2%, 17.2%, and 10.7%, respectively. 👉Among top brands, #Monocef, #Electral, #Augmentin and #Budecort showed >40% value growth in June 2024. ♥️Source – PHARMATRAC MAT JUNE 2024

The September 8th issue of Pharmaceutical Technology contained an interesting article on "Subcutaneous drugs grant a new lease on life to checkpoint inhibitors." Subcutaneous drugs offer the following benefits: * Quality of life for the patient. The subcutaneous medication can be delivered faster than an IV solution. * Reduced healthcare cost by having the subcutaneous drug administered in a doctor's office outside of a hospital. Subcutaneous drugs have a fixed dosage. * Subcutaneous applications offer new life to drugs administered by IV that will come off patent (e.g. Keytruda 2028). Halozyme will benefit from the focus on subcutaneous delivery of medications.

Unleash the potential of our Antiparasitic Bulk Drug for comprehensive parasite control. Elevate your pharmaceutical offerings with a touch of effectiveness and reliability. 🏥💊 #ParasiteManagement #HealthcareExcellence

STATINS mechanism of action.... Statins include: atorvastatin (Lipitor) fluvastatin (Lescol) lovastatin (Mevacor) pravastatin (Pravachol) rosuvastatin (Crestor) simvastatin (Zocor) List your Pharmaceutical Finished Products on www.listmydrug.com and get connected to global buyers for free. Write us on info@listmydrug.com #statins #cholesterol #pharmaceutical #listmydrug

🌈𝐃𝐫𝐮𝐠 𝐫𝐞𝐜𝐚𝐥𝐥: 𝐃𝐢𝐠𝐨𝐱𝐢𝐧 𝐓𝐚𝐛𝐥𝐞𝐭𝐬 𝐫𝐞𝐜𝐚𝐥𝐥𝐞𝐝 𝐝𝐮𝐞 𝐭𝐨 𝐥𝐚𝐛𝐞𝐥 𝐦𝐢𝐱-𝐮𝐩 🍁Drug recall: In New Castle, Delaware, Marlex Pharmaceuticals, Inc. is voluntarily recalling one lot of Digoxin Tablets USP, 0.125 mg, and one lot of Digoxin Tablets USP, 0.25 mg, to the consumer level due to a label mix-Up. 🍁Bottles of Digoxin Tablets, USP 0.125mg, are incorrectly labeled and contain Digoxin Tablets, USP, 0.25mg. Bottles of Digoxin Tablets USP, 0.25 mg, are incorrectly labeled and contain Digoxin Tablets USP, 0.125mg. 🍁The mix-up in labels can cause either overdosing or underdosing in patients who unknowingly take the wrong dose. 🍁Patients who intend to take Digoxin Tablets USP, 0.25mg, but unknowingly take Digoxin 0.125mg would receive a sub potent dose, which may lead to loss of control of heart rate and a potential heart failure exacerbation. Source: Thehealthmaster #pharma #pharmaceutical

General terms :In use stability studies In the pharmaceutical industry, in-use stability studies assess the stability of a drug product after it has been opened or reconstituted by the end user. These studies evaluate factors such as potency, purity, and degradation over a specified period, ensuring the product remains safe and effective during actual use. They help establish appropriate storage conditions and expiration dates for opened or reconstituted pharmaceuticals, enhancing patient safety and product quality.

𝗧𝗵𝗲 𝗥𝗶𝘀𝗲 𝗼𝗳 𝗣𝗿𝗲-𝗙𝗶𝗹𝗹𝗲𝗱 𝗦𝘆𝗿𝗶𝗻𝗴𝗲𝘀: 𝗔 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗚𝗲𝘁 𝗣𝗗𝗙 𝗖𝗼𝗽𝘆@https://lnkd.in/dfsYx5KT Prefilled syringes are pharmaceutical product which is used to deliver parenteral medications. Pre-filled syringe contract manufacturing involves a single dose of parenteral drug incorporated into the delivery device by the syringe manufacturer. The Global Pre-Filled Syringes Market Size was estimated at USD 4479.10 million in 2021 and is projected to reach USD 5360.71 million by 2028, exhibiting a CAGR of 2.60% during the forecast period. 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬  • BD • Gerresheimer • SCHOTT • Nipro Medical Corporation • Roselabs Limited • @Fresenius Kabi • Baxter International Inc. • West-Coast Pharma #PreFilledSyringes,#Pharmaceuticals,#MedicalDevices,#DrugDelivery,#Biotechnology,#Healthcare,#Innovation,#MedTech,#PatientSafety,#InjectionSafety,#HealthTech,#MedicalInnovation,#QualityControl,#Biologics,#Vaccines

Explore the relationship between GLP-1 receptor agonist brands and Medicare Part-D diabetes adherence metrics in our latest publication. Discover how potential shifts in drug use for weight loss purposes may have influenced dosing and therapy patterns. Insights that matter for pharmaceutical strategies. Read the full study here: https://ow.ly/SpMo50QkBob . . . #AIHealthcare #PatientOutcomes #MedicationAdherence #PredictiveAI #GLP1

Struggling to create stable Emulgel? Understand it's not easy to make. Don't worry, Crodamol CCC alongside with our other ingredients will help you creating it. Contact me for free sample, formulation guide, and technical consultation with our expert Dhanila Varkey, PhD (Pharm Tech) Yudi Clements Puteri Dyah Nastiti #crodapharma #crodapharmaceutical #croda #topicalformulation #topical #topicalpharma

𝗧𝗵𝗲 𝗥𝗶𝘀𝗲 𝗼𝗳 𝗣𝗿𝗲-𝗙𝗶𝗹𝗹𝗲𝗱 𝗦𝘆𝗿𝗶𝗻𝗴𝗲𝘀: 𝗔 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗚𝗲𝘁 𝗣𝗗𝗙 𝗖𝗼𝗽𝘆@https://lnkd.in/dfsYx5KT Prefilled syringes are pharmaceutical product which is used to deliver parenteral medications. Pre-filled syringe contract manufacturing involves a single dose of parenteral drug incorporated into the delivery device by the syringe manufacturer. The Global Pre-Filled Syringes Market Size was estimated at USD 4479.10 million in 2021 and is projected to reach USD 5360.71 million by 2028, exhibiting a CAGR of 2.60% during the forecast period. 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬  • BD • Gerresheimer • SCHOTT • Nipro Medical Corporation • Roselabs Limited • Fresenius Kabi • Baxter International Inc. • WEST PHARMA #PreFilledSyringes,#Pharmaceuticals,#MedicalDevices,#DrugDelivery,#Biotechnology,#Healthcare,#Innovation,#MedTech,#PatientSafety,#InjectionSafety,#HealthTech,#MedicalInnovation,#QualityControl,#Biologics,#Vaccines